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Abstract 
Background: Epidermal growth factor receptor (EGFR) is an important oncogenic protein in multiple types of cancer. 
Endocytosis and degradation of epidermal growth factor receptor (EGFR) are two key steps for down-regulation of 
cell surface level of EGFR and modulation of EGFR signaling. Stress conditions induce ligand-independent endocytosis 
and degradation of EGFR. However, it is not clear whether stress-induced endocytosis and degradation are conse-
quential or two independent events.
Methods: Endocytosis and degradation of EGFR in response to stress treatment and effects of the p38 inhibitor, the 
Caspase-3 inhibitor and the proteasomal inhibitor in cervical cancer HeLa cells were determined using immunoblot-
ting and immunofluorescent staining assays.
Results: Stress conditions, such as protein biosynthesis inhibition, UV light irradiation, and hyper-osmosis, induced 
both ligand-independent endocytosis and degradation of EGFR. Stress-induced endocytosis of EGFR relies on p38 
kinase activity, while stress-induced degradation of EGFR is catalyzed by Caspase-3 activity. Inhibiting p38 kinase 
impairs only the endocytosis but not the degradation, while inhibiting Caspase-3 results in the opposite effect to 
inhibiting p38. Furthermore, proteasomal activity is required for stress-induced degradation of EGFR and cell death, 
but not for endocytosis.
Conclusions: The results indicate that stress-induced endocytosis and degradation are two independent events and 
suggest stress signaling may utilize a double-secure mechanism to down-regulate cell surface EGFR in cancer cells.
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Background
The receptor tyrosine kinase (RTK) EGFR plays impor-
tant roles in cell growth, survival, differentiation, and 
transformation [1–5]. Down-regulation of cell surface 
EGFR is a major process for attenuating EGFR signaling, 
especially for the signaling that occurs on plasma mem-
brane [6–9]. Defects in down-regulation, mainly endo-
cytosis and degradation processes, of cell surface EGFR 
may cause constitutive activation of cell proliferation and 
survival signaling and lead to oncogenesis and tumor 
progression [10–12].
There are two major pathways for down-regulation 
of cell surface EGFR in cells. One is the ligand-induced 
endocytosis and degradation of EGFR and the other is 
stress-induced endocytosis and degradation. The ligand-
induced endocytosis and degradation of EGFR have been 
extensively studied [13–16]. Upon activation by a ligand, 
such as EGF, EGFR is tyrosine-phosphorylated, and sub-
sequently recruits Cbl, an E3 ubiquitin ligase, and Grb2, 
an adaptor protein, for assembly of the ubiquitination 
complex, and interacts with Eps15 and AP-2, two endo-
cytic adaptor proteins, to form clathrin-coated endocytic 
vesicles [17–19]. The endocytic vesicles or endosomes 
containing ubiquitinated EGFR are recognized by the 
ubiquitin-binding protein Hrs and transported to multi-
vesicular bodies (MVBs) [20, 21]. Finally, the MVBs fuse 
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with lysosomes to complete degradation of EGFR. In this 
ligand-induced endocytosis and degradation of EGFR, 
tyrosine phosphorylation and ubiquitination are two key 
biochemical processes, in which the tyrosine phosphoryl-
ation is required for organization of the endocytosis and 
ubiquitination complexes, and the ubiquitination func-
tions as a sorting signal for transport of the EGFR-loaded 
vesicles to lysosomes. In addition, endocytosis and deg-
radation are two consequential events in ligand-induced 
down-regulation of EGFR, in which the degradation pro-
cess is dependent on the endocytosis.
Stress conditions, such as UV irradiation, inflam-
matory cytokines, osmotic stress, oxidation stress and 
protein biosynthesis inhibition, induce endocytosis and 
degradation of EGFR independent of ligand stimulation 
[22–24]. The stress-induced endocytosis and degrada-
tion of EGFR have distinguished biochemical processes 
from ligand-induced endocytosis and degradation. 
First, no tyrosine phosphorylation or ubiquitination is 
required for initiation of stress-induced endocytosis of 
EGFR [22]. Second, activation of p38 kinase is essen-
tial for stress-induced endocytosis of EGFR [22]. Third, 
lysosomes, which are required for ligand-induced deg-
radation of EGFR, are not involved in stress-induced 
degradation [25]. However, assembly of endocytic vesi-
cles in stress-induced endocytosis of EGFR, similar to in 
ligand-induced endocytosis, is mediated by the adaptor 
protein AP2 and coated by clathrin [26–28]. Whether 
stress-induced degradation of EGFR is dependent on 
proteasomes or caspases is still in dispute [22, 25]. 
Furthermore, the connection between endocytosis 
and degradation is not characterized in stress-induced 
down-regulation of EGFR.
Both ligand- and stress-induced endocytosis and deg-
radation of EGFR have been observed in cancer cells [27, 
29–31]. Most of studies on the ligand-induced endocy-
tosis and degradation of EGFR have been characterized 
in cervical cancer HeLa cells. Although ligand-induced 
endocytosis was initially thought to be an important 
means to down-regulate cell surface EGFR, subsequent 
studies found that endocytic EGFR in cancer cells con-
tinues generating signals on endosomes that differ from 
on plasma membrane [32, 33]. The cellular signaling 
involving stress-induced endocytosis currently is not 
well understood and poorly characterized. It has been 
observed that stress-induced endocytosis potentiates 
the chemotherapy drug-induced apoptosis [27, 29]. A 
very recent report found that in HeLa cells UV irradia-
tion or cisplatin-induced endocytosis of EGFR utilizes a 
completely different trafficking route from EGF-induced 
endocytosis [29]. The stress-induced endocytic EGFR is 
accumulated in a subpopulation of lyso-bisphosphatidic 
acid (LBPA)-rich multivescular bodies (MVBs) that are 
distinguishable from the MVBs containing EGF-induced 
endocytic EGFR [29]. Furthermore, impairment of the 
stress-induced EGFR endocytosis enhanced UV-irradia-
tion or cisplatin-induced apoptosis [29], suggesting that 
the stress-induced endocytosis of EGFR might play a role 
in antagonizing the stress-induced apoptosis in cancer 
cells.
In this report, we show that stress conditions, including 
protein synthesis inhibition, UV irradiation, and hyper-
osmosis, cause endocytosis and degradation of EGFR in 
cervical cancer HeLa cells. Our data demonstrate that the 
stress-induced activation of p38 kinase is required for the 
endocytosis of EGFR while the activation of Caspase-3 
is for the degradation. Furthermore, the p38 activation-
induced internalization and the Caspase 3-mediated deg-
radation are two independent events in stress-induced 
down-regulation of cell surface EGFR. However, these 
two processes seem coordinated in timing because the 
internalization precedes the degradation. We propose 
that stress conditions down-regulate cell surface EGFR in 
cancer cells by the two coordinated but independent pro-
cesses, i.e., the p38-mediated endocytosis and the Cas-
pase-3-catalyzed degradation of EGFR, to impede cancer 
cell proliferation.
Results
Protein synthesis inhibition, UV irradiation or 
hyperosmosis induces degradation of EGFR in HeLa cells
Previous studies have shown that treatments of aniso-
mycin or UV irradiation with cervical cancer HeLa cells 
induced degradation of EGFR [22]. To confirm the effect 
of stress conditions on EGFR endocytosis and degrada-
tion, in addition to UV irradiation and anisomycin, we 
also examined effects of 0.7  M NaCl (hyper-osmosis) 
and protein synthesis inhibitor puromycin on EGFR deg-
radation in HeLa cells. As shown in Fig. 1, all the stress 
conditions caused significant degradation of EGFR upon 
3 h treatments (lanes 5, 9, 14 and 19). In general, about 
70–80 % of total EGFR in whole cell lysates was degraded 
upon 3  h treatment of stress conditions in HeLa cells 
(data not shown). Comparing to ligand (EGF)-induced 
degradation of EGFR (lanes 20–24), stress-induced deg-
radation of EGFR has two distinguishable traits: (i) the 
degradation rate is much slower than that of ligand-
induced degradation; and (ii) the degradation products 
are different from that of ligand-induced degradation. No 
degradation products were detected by immunoblotting 
with anti-EGFR (Santa Cruz, 1005) in stress treated cells, 
while a degraded EGFR band was detected upon 0.5, 1 
and 2 h EGF stimulation (lanes 21–23, Fig. 1). These data 
suggest that the molecular mechanism underlying stress-
induced degradation is different from that of ligand-
induced degradation.
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Caspase activity but not p38 kinase activity is required 
for stress‑induced degradation of EGFR
Ligand-induced degradation of EGFR requires activa-
tion of EGFR because the E3 ubiquitin-ligase Cbl is 
recruited to active EGFR by binding to phosphotyrosine 
1045 (pY1045) for ubiquitination of EGFR and Cbl-cat-
alyzed ubiquitination is the sorting signal for transport 
to lysosomes for degradation. This mechanism does not 
apply to stress-induced degradation of EGFR because no 
activation of EGFR or Cbl-binding to EGFR is required 
for stress-induced degradation of EGFR. Previous stud-
ies demonstrated that stress-induced activation of p38 
kinase or Caspase-3 plays an important role in anisomy-
cin- and UV irradiation-induced degradation of EGFR 
[22, 25]. However, the molecular mechanism underly-
ing stress-induced degradation of EGFR has not been 
fully understood. To elucidate the molecular mechanism 
underlying stress-induced degradation of EGFR, we first 
examined the effect of inhibitors of caspases, p38 kinase 
(SB203850) or MEK1/2 (U0126) on stress-induced deg-
radation of EGFR. As shown in Fig. 2a, b, caspase inhibi-
tor mix blocked all stress-induced degradation of EGFR 
(lanes 7, 8, 13, 14, 19 and 20, Fig. 2a; panels II, III, and IV, 
Fig. 2b), but did not affect ligand (EGF)-induced degra-
dation of EGFR (lanes 1 and 2, Fig. 2a; panel I, Fig. 2b), 
indicating that all stress-induced degradation of EGFR is 
mediated by caspases, while ligand (EGF)-induced deg-
radation of EGFR is not dependent on caspase activity. 
To our surprise, p38 inhibitor SB203850 had a minor 
inhibitory effect (about 30  %) on ligand (EGF)-induced 
degradation of EGFR (lanes 3 and 4, Fig.  2a; panel I, 
Fig. 2b), and no effect on stress-induced degradation of 
EGFR (lanes 9, 10, 15, 16, 21, and 22, Fig. 2a; panels II, 
III, and IV, Fig.  2b), suggesting that p38 kinase activity 
is not required for stress-induced degradation of EGFR. 
Interestingly, the MEK1/2 inhibitor U0126 had a par-
tial inhibitory effect (50  %) on anisomycin- and 0.7  M 
NaCl-induced degradation of EGFR (lanes 11, 12, 23, 
and 24, Fig. 2a; panels II and IV, Fig. 2b), without affect-
ing ligand (EGF)-induced and UV irradiation-induced 
degradation of EGFR (lanes 5, 6, 17, and 18, Fig. 2a; pan-
els I and III, Fig. 2b). Currently, the mechanism underly-
ing inhibitory effect of the MEK1/2 inhibitor U0126 on 
the stress-induced EGFR degradation is unknown.
It has been reported that EGFR has caspase cleavage 
sites and is a substrate of Caspase-3 [25]. To further con-
firm that Caspase-3 is crucial for degradation of EGFR, 
we determined effect of an inhibitor of Caspase-3 on 
stress-induced degradation of EGFR. As shown in Fig. 2c, 
the Caspase-3 inhibitor specifically inhibited the deg-
radation induced by anisomycin and UV-irradiation, 
indicating that Caspase-3 is the caspase involved in 
stress-induced degradation of EGFR.
Taken together, stress-activated Caspase-3 activity is 
the cause for stress-induced degradation of EGFR, while 
stress-activated p38 kinase activity is not required for 
stress-induced degradation of EGFR.
Stress‑activated p38 kinase activity but not Caspase‑3 
activity is required for stress‑induced endocytosis of EGFR
It has been shown that stress-induced endocytosis of 
EGFR is independent of ligand stimulation and impaired 
by inhibition of the p38 kinase activity [22]. To define the 
role of p38 kinase in stress-induced degradation of EGFR, 
we examined effects of inhibitors of Caspase-3, p38 and 
MEK1/2 kinases on stress-induced endocytosis assayed 
by immunofluorescent staining with anti-EGFR. As 
shown in Fig. 3A, B, after 60 min treatment of anisomycin 
or UV-irradiation, EGFR was endocytosed (panels a and 
e). The treatment of inhibitors of Caspase-3 and MEK1/2 
kinases on the cells did not block the stress-induced 
endocytosis of EGFR (panels b, d, f and h, Fig.  3A, B). 
However, SB203850, the inhibitor of p38 kinase, com-
pletely diminished the stress-induced endocytosis of 
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Fig. 1 Both physical and chemical stress conditions induce degradation of EGFR. HeLa cells were cultured in DMEM plus 10 % FBS to 90 % conflu-
ence and serum-starved for 12 h. For puromycin (5 μg/ml), anisomycin (60 μM) or EGF (100 ng/ml) treatment, the stock solution of the chemical was 
added to the medium for indicated time. For 0.7 M NaCl treatment, the cells were cultured in serum-free DMEM medium plus 0.7 M NaCl for indi-
cated time. For UV treatment, the cells were irradiated under a UV light (about 8 J/cm2) for 2 min, then cultured in serum-free medium for indicated 
time. The cells were lysed and EGFR was immunoprecipitated with anti-EGFR (Mab528) and detected by immunoblotting with anti-EGFR(1005). The 
amount of lysates used for Immunoprecipitation was controlled by immunoblotting of β-actin (bottom panels) in whole cell lysates with anti-β-
actin
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EGFR (panels c and g, Fig. 3A, B). As a control, we exam-
ined the effect of the inhibitors on ligand-induced endo-
cytosis of EGFR, as shown in Fig.  3C. Consistent with 
the effect on ligand-induced degradation of EGFR, the 
inhibitors did not affect the ligand-induced endocytosis 
of EGFR, suggesting that ligand-induced endocytosis uti-
lizes a different mechanism from that of stress-induced 
endocytosis.
To confirm that p38 kinase inhibitor blocks stress-
induced endocytosis of EGFR, we also employed an 
alternative biochemical approach in addition to the 
immunofluorecent staining. We labeled cell surface 
EGFR with biotin at different time points of anisomy-
cin treatment in presence or absence of the p38 kinase 
inhibitor SB203850. The biotin-labeled EGFR was then 
immunoprecipitated with anti-EGFR (Mab528) and 
detected by immunoblotting with anti-EGFR (1005) 
(Santa Cruz). As shown in Fig. 3D, endocytosis of EGFR 
reached to more than 90 % of completion upon 30 min 
treatment (lane 2, upper panel) and 100 % of completion 
Fig. 2 Caspase inhibitor blocks stress-induced degradation but not EGF (ligand)-induced degradation of EGFR. HeLa cells were cultured and serum-
starved the same as described in Fig. 1. The caspase inhibitor mix (the caspase inhibitor mix, 2 μM each), Caspase-3 inhibitor (20 μM), p38 kinase 
inhibitor SB203850, or MEK1/2 inhibitor U0126 was added to the cells 30 min before the treatment of EGF, anisomycin, 0.7 M NaCl, or UV irradiation. 
The treatment of EGF and the stress conditions for inducing EGFR degradation was for 3 h. EGFR was immunoprecipitated with anti-EGFR(Mab528) 
and detected by immunoblotting with anti-EGFR (1005). a and c Western blot of EGFR (the top panel) and β-actin in whole cell lysates (the bot-
tom panel) with immunoblotting. b Quantification of the immunoblotting data from three repetitions of experiments in (a). *p < 0.05, **p < 0.01, 
***p < 0.001
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upon 60  min treatment of anisomycin (lane 3, upper 
panel). Addition of the p38 kinase inhibitor SB203850 
to the anisomycin treatment blocked more than 90 % of 
anisomycin-induced endocytosis of EGFR (lanes 4–6, 
upper panel, Fig.  3D), confirming that stress-activated 
p38 kinase activity is indeed required for stress-induced 
endocytosis of EGFR.
Taken together, these data indicate that stress-activated 
p38 kinase activity is required for stress-induced endo-
cytosis of EGFR, while Caspase-3 and MEK1/2 kinase 
activity are not involved in stress-induced endocytosis. 
In addition, these data have demonstrated that stress-
induced endocytosis and degradation of EGFR are two 
independent cellular processes, which is different from 
that of ligand-induced endocytosis and degradation.
Proteasomal activity is required for stress‑induced 
degradation but not endocytosis of EGFR
Previous studies have shown that the proteasome inhibi-
tor MG-132 completely blocked anisomycin-induced 
degradation of EGFR and proposed that proteasomes 
may execute the anisomycin-induced degradation of 
EGFR [22]. To examine the role of proteasome in stress-
induced endocytosis and degradation, we treated HeLa 
cells with MG-132 prior to stress treatments. As shown 
in Fig.  4A, B, MG-132 completely blocked anisomycin-, 
0.7  M NaCl- and UV irradiation-induced degradation 
of EGFR (lanes 2–7, Fig.  4A, B), but not ligand (EGF)-
induced degradation of EGFR (lanes 8 and 9; Fig. 4A, B). 
This data suggest that the proteasome activity is required 
for stress-induced degradation of EGFR.
To determine if MG-132 affects stress-induced endocy-
tosis of EGFR, we performed immunofluorescent stain-
ing with anti-EGFR under stress conditions in presence 
or absence of MG-132. As shown Fig.  4C, MG-132 did 
not significantly affect the anisomycin- 0.7 M NaCl- and 
UV-irradiation-induced endocytosis of EGFR, suggest-
ing that proteasomal activity is not essential for stress-
induced endocytosis.
Because ubiquitination of EGFR has not been observed 
upon stress treatments [22], it is unlikely that proteaso-
mal activity directly mediates stress-induced degradation 
of EGFR. Furthermore, Caspase-3 activity is essential 
for stress-induced degradation of EGFR (Fig.  2). Thus, 
Fig. 3 p38 kinase activity is required for stress-induced endocytosis of EGFR. A–C HeLa cells were cultured on glass cover slip-bottomed dishes 
(Matek) and serum-starved in DMEM plus 1 % FBS for 12 h. The Caspase-3 inhibitor, p38 kinase inhibitor SB203850 or MEK inhibitor U0126 was 
added into the medium 30 min before the treatment of EGF, anisomycin or UV irradiation. Then the cells were fixed and immunostained with anti-
EGFR(1005) as described in “Methods” section. Bar 20 μm. D HeLa cells were biotin-labeled after treatment of anisomycin. The biotin-labeled EGFR 
was immunoprecipitated by anti-EGFR(Mab528) and detected by immunoblotting with anti-biotin (the top panel). The relative amount of lysates 
used for immunoprecipitation was controlled by immunoblotting of β-actin in the lysates (the bottom panel)
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we speculate that proteasomal activity may be required 
for stress-induced activation of Caspase-3. In fact, we 
observed that MG-132 protected the cells from apoptosis 
induced by treatment of anisomycin or UV irradiation as 
evaluated by cell survival rate (Fig. 4D), strongly suggest-
ing that proteasome activity is required for caspase-initi-
ated apoptosis, as described by Sohn et al. [34]. However, 
further investigation is needed to clarify the role of pro-
teasomal activity in stress-induced activation of caspases 
and degradation of EGFR.
Stress‑induced endocytosis of EGFR may coordinate 
with the stress‑induced degradation
Although stress-induced endocytosis and degradation 
are two independent events, they may coordinate each 
other in cells to down-regulate EGFR and eliminate 
EGFR signaling under stress conditions. To examine the 
coordination between the endocytosis and the degrada-
tion, we performed the stress-induced endocytosis assay 
by immunofluorescent staining of EGFR in parallel with 
the stress-induced degradation assay by immunoblot-
ting of EGFR and compared the progression in these two 
processes. As shown in Fig.  5A, endocytosis of EGFR 
induced by anisomycin or UV-irradiation reached to 
maximum level within 15 min treatment (panels b and f ). 
At the same time point, the degradation of EGFR did not 
occur (lanes 2 and 8, Fig. 5B). The data in Fig. 5A, B indi-
cate that stress-induced endocytosis of EGFR precedes 
stress-induced degradation of EGFR, implicating that 
stress-induced endocytosis and degradation could be two 
coordinated processes. The sequential order of stress-
induced endocytosis and degradation of EGFR may be 
critical for cells to completely shut down EGFR signaling 
under stress conditions.
Fig. 4 Proteasomal activity is required for stress-induced degradation of EGFR and cell death, but not endocytosis of EGFR. HeLa cells were cultured 
and serum-starved the same as described in Fig. 1. The proteasome inhibitor MG-132 (10 μM) was added to the cells 30 min prior to the treatment 
of EGF, anisomycin, UV irradiation or 0.7 M NaCl. A The cells were lysed and EGFR was immunoprecipitated and detected by immunoblotting with 
anti-EGFR(1005) (the top panel). B The immunoblotting data of EGFR from three repetitions of experiments was quantified by Kodak EDAS290 image 
system. ***p < 0.001. C Examination of effect of MG-132 on stress-induced endocytosis of EGFR by immunofluorescent staining of EGFR. The experi-
mental procedures were the same as described in Fig. 3A–C Bar 20 μm. D MG-132 protects stress-induced cell death. The cells were incubated in 
MG-132 (10 μM)-contained medium 30 min prior to the treatment of anisomycin or UV irradiation. The viable cell numbers were counted under a 
microscope with a hemacytometer. The relative cell survival was plotted as percentage of the control cell numbers. In statistical analysis, the sam-
ples treated with MG-132 alone are used as the control data set. *p < 0.05, **p < 0.01, ***p < 0.001
Page 7 of 10Peng et al. Cancer Cell Int  (2016) 16:25 
Discussion
Our studies have shown that both chemical and physical 
stress conditions induce endocytosis and degradation of 
EGFR in cervical cancer HeLa cells (Fig. 1). By employ-
ing inhibitors of p38 kinase and Caspase-3, we dem-
onstrated that activation of p38 kinase and Caspase-3 
are two major biochemical processes in stress-induced 
endocytosis and degradation of EGFR (Fig. 2). Our data 
indicate that stress-induced endocytosis and degradation 
are two independent processes, since inhibition of p38 
kinase impairs the endocytosis but not the degradation, 
while inhibition of Caspase-3 blocks the degradation but 
not the endocytosis (Figs. 2, 3).
In the ligand-induced degradation, EGFR is first inter-
nalized then transported to lysosomes for degradation, 
thus endocytosis is required for the degradation. In the 
stress-induced degradation, EGFR is directly cleaved 
by stress-activated Caspase-3, thus endocytosis is not 
required for the degradation. We observed that upon 
treatment with UV irradiation or anisomycin quickly 
induced endocytosis of EGFR much earlier than the deg-
radation (Fig.  5), suggesting that the endocytosis might 
coordinate with the degradation. We speculate that 
stress-induced endocytosis of EGFR is critical for com-
pletion of down-regulation of cell surface EGFR signaling. 
Because Caspase-3 cleavage sites in EGFR are localized 
in the regulatory region of cytoplasmic portion [25], the 
Caspase-3-cleaved (degraded) EGFR is still able to bind 
to its ligands and partially transduce signals mediated 
by the kinase domain if it is retained on plasma mem-
branes. The stress-induced endocytosis enables EGFR 
quickly to separate from its extracellular ligands thus to 
Fig. 5 Stress-induced endocytosis is coordinated with the degradation of EGFR. The same batch of HeLa cells were used for examining the time 
scale of stress-induced endocytosis and degradation analyzed by immunofluorescent staining (A) or immunoblotting (B) with anti-EGFR(1005). The 
treatment of anisomycin or UV irradiation in samples for examination of EGFR endocytosis (immunofluorescent staining) was performed in parallel 
with that for immunofluorescent staining. The experimental procedures were the same as described in Figs. 1 and 2. Bar 20 μm
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minimize the EGFR signaling. Therefore, stress-induced 
endocytosis might be necessary for completely shutting 
down the EGFR signaling. Consistent with our specula-
tion, Zwang and Yarden [27] observed that p38 mediated 
stress-induced endocytosis of EGFR augmented cyto-
toxicity produced by chemotherapeutic agents in HeLa 
cells, suggesting that stress-induced endocytosis of EGFR 
is important for down-regulating EGFR-mediated anti-
apoptotic signaling in the cervical cancer cells.
However, a recent research article showed that stress-
induced endocytosis is required for endosomal EGFR 
activation and defect in the endocytosis enhances the 
UV irradiation- or cisplatin-induced apoptosis in HeLa 
cells [29], suggesting that the stress-induced endocytosis 
is important for EGFR to generate endosomal anti-apop-
totic signaling. The role of the stress-induced endocytosis 
defined in this report is inconsistent with the report from 
Zwang and Yarden [27]. To clarify the discrepancy on the 
role of stress-induced endocytosis of EGFR in chemo-
therapy-induced cancer cell apoptosis, further studies are 
needed.
We observed that the MEK1/2 inhibitor U0126 had 
a significant inhibitory effect on anisomycin- or 0.7  M 
NaCl- induced degradation of EGFR (Fig. 2a, b), suggest-
ing that MEK1/2 and Erk activation might be involved 
in stress-induced activation of Caspase-3 for degrading 
EGFR. There are several lines of evidence showing that 
activation of Erk is involved in stress-induced apopto-
sis [35, 36]. Our results are consistent with the observa-
tion that Erk activation is required for chemical stress 
(cisplatin treatment)-induced apoptosis but not for 
UV-induced apoptosis [37]. However, we do not know 
why Erk plays a role in chemical stress-induced apop-
tosis but not in UV-induced apoptosis. One possibility 
is that Erk is not involved in ROS-mediated stress sign-
aling since PD98059 did not have an effect on oxidant-
induced apoptosis [37]. Further investigation is required 
for understanding exact roles of MEK1/2 and Erk1/2 in 
regulation of stress signaling.
In addition, we observed that the proteasomal inhibitor 
MG-132 impaired stress-induced degradation, but not 
endocytosis of EGFR (Fig.  4), suggesting that proteaso-
mal activity might be involved in regulation of the stress-
induced degradation process. It has been reported that 
proteasomes down-regulate a number of ubiquitinated 
anti-apoptotic proteins [38]. The effect of MG-132 on 
protection of stress-induced degradation of EGFR may 
result from stabilization of ubiquitinated anti-apoptotic 
proteins. It is interesting to look into the role of ubiqui-
tination in regulation of stress-induced degradation of 
EGFR in future studies.
How p38 kinase activation induces endocytosis of 
EGFR is still not fully understood. It has been observed 
that activation of p38 kinase facilitates ligand-induced 
degradation of EGFR in COS7 cells [39]. Inhibiting p38 
kinase by the kinase inhibitor or knockdown by RNAi 
causes significant reduction of tyrosine phosphorylation 
at Y1045 of EGFR, which is required for EGFR binding to 
the E3 ubiquitin ligase Cbl, thus results in defect in ubiq-
uitination and degradation of EGFR [39]. However, p38 
kinase activity did not affect ligand-induced internaliza-
tion of EGFR [39], which is consistent with our results 
shown in Fig. 3C. We observed only a partial inhibition 
of ligand-induced degradation of EGFR by suppression 
of p38 kinase activity with SB203850 (Fig.  2b-I). It has 
been observed that stress conditions, such as treatment 
with cisplatin, anisomycin or UV irradiation, induce 
phosphorylation of EGFR through activation of p38 [27]. 
This p38 mediated phosphorylation is required for stress-
induced internalization of cell surface EGFR [40, 41]. Pre-
vious studies have demonstrated that the stress-induced 
endocytosis of EGFR was mediated by clathrin-coated 
vesicles [26–28]. The phosphorylation of EGFR by acti-
vated p38 kinase upon stress treatment might function 
in recruiting adaptor protein AP2 for assembly of clath-
rin-mediated endocytic complex of EGFR. However, the 
exact role of p38-mediated phosphorylation of EGFR in 
stress-induced endocytosis of EGFR is still not known 
and needs to be defined by further investigation.
Conclusions
Stress conditions induced endocytosis and degradation 
of EGFR independent of ligand stimulation in cervical 
cancer HeLa cells. Unlike ligand-induced endocytosis 
and degradation that are consequential events, the stress-
induced endocytosis and degradation are two inde-
pendent events. Stress-induced endocytosis of EGFR is 
dependent on p38 kinase and the degradation is cata-
lyzed by Caspase-3. In addition, proteasomal activity is 
also required for stress-induced degradation, but not 
endocytosis, of EGFR. We propose that the cancer cells 
utilize a double-secure way to down-regulate cell surface 
EGFR in response to stress conditions.
Methods
Materials
EGF was purchased from Invitrogen (Gibco); SB203850, 
U0126 and MG-132 were purchased from CalBiochem; 
Caspase inhibitor mix and Caspase-3 inhibitor were pur-
chased from Biovision; anisomycin and puromycin were 
purchased from Sigma. Anti-EGFR antibody (1005) was 
purchased from Santa Cruz Biotechnology; anti-EGFR 
Mab528 was obtained from the culture medium of the 
hybridoma cell line 528 purchased from ATCC. Anti-β-
Actin was purchased from Sigma. The biotin-labeling kit 
was purchased from Pierece.
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Cell culture and treatments
The cervical cancer HeLa cells were cultured in DMEM 
plus 10  % FBS with 5  % CO2. The cells were starved in 
serum-free medium overnight before the treatment. The 
time course of the treatments, including EGF (100  ng/
ml), anisomycin (60  μM), puromycin (5  μg/ml) and 
NaCl (0.7 M), was done in a reverse way, i.e., the longest 
treatment was done first and the shortest treatment was 
done last, so all the treated cells were harvested at the 
same time. For inhibition of Caspase-3, p38 kinase and 
MEK1/2 kinase activity, the inhibitors were added 30 min 
before the treatments of EGF, anisomycin, NaCl, or UV 
irradiation. For UV irradiation, the culture medium was 
removed and the cells on culture dishes were directly 
exposed to UV irradiation at about 8  J/cm2 for 2  min, 
subsequently cultured in replenished culture medium for 
indicated time (referred as UV treatment time).
Immunoprecipitation and immunoblots
The cells were rinsed with PBS once and lysed with 
the lysis buffer (40  mM Hepes, pH 7.4, 100  mM NaCl, 
1  % Triton X-100, 25  mM β-glycerophosphate, 1  mM 
sodium orthervanadate, 10  μg/ml leupeptin and 10  μg/
ml aprotinin) (0.5 ml/60 mm dish) with rocking at 4  °C 
for 20 min. The cell lysates were collected into an eppen-
dorf tube and cleared by centrifugation at 14,000 rpm for 
4 min in a microfuge. The cleared lysates were transferred 
to a clean eppendorf tube and incubated with primary 
antibody on ice for 30 min, then protein A or protein G 
beads were added and the mixture is incubated at 4 °C for 
2 h with rotation. The beads were washed with lysis buffer 
three times. The immunoprecipitation complexes were 
directly dissolved in SDS-PAGE sample buffer and sepa-
rated by SDS-PAGE. The immunoblot was performed as 
instructed by ECL immunoblot kits (Amersham).
Immunofluorescent staining
The cells were cultured in glass bottom microwell 
dishes (MatTek) to 50–80  % confluence. After the cul-
ture medium was removed, the cells were rinsed with 
PBS twice, fixed with 3.7  % paraformaldehyde at 25  °C 
for 10 min and permeablized with 0.2 % Triton X-100 in 
PBS at 25 °C for 10 min. Following washing with PBS, the 
cells were incubated with primary antibody at 25  °C for 
60 min. Then the cells were washed with PBS three times 
and incubated with secondary antibody that was conju-
gated with a fluorescent dye at 25 °C for 60 min. Finally, 
the cells were washed with PBS three times (for 10 min 
each) and incubated in PBS. Immunofluorescence stain-
ing was visualized with a Nikon inverted fluorescent 
microscope.
Biotin labeling in determination of stress‑induced 
internalization of EGFR
HeLa cells were cultured in DMEM plus 10 % FBS to 90 % 
confluence, then serum-starved for 6 h, following by the 
treatment with anisomycin (60  μM) for indicated time. 
The p38 kinase inhibitor SB203850 was added to the cells 
30  min prior to anisomycin treatment. For biotin labe-
ling of cell surface EGFR, pre-cooled (4  °C) sulfo-NHS-
SS-biotin (Pierce) (1.5  mg/ml) in DMEM was added to 
the cells immediately after anisomycin treatment, and 
incubated with the cells on ice for 30 min for labeling cell 
surface proteins. The cells were lysed with the lysis buffer 
and EGFR was immunoprecipitated with anti-EGFR 
(Mab528). The biotin-labeled EGFR was detected by 
immunoblotting with an anti-biotin antibody. The equal-
ity of amount of cell lysates used for immunoprecipita-
tion among the samples was evaluated by the amount of 
β-actin in the lysates that was determined by immunob-
lotting with anti-β-actin antibody.
Cell viability assay
Cells were plated to a 12-well plate incubating in 1  ml 
of media per well. Each treatment group was plated and 
counted in triplicate. At the indicated times for counting, 
the media was removed and 0.5 ml of trypsin/0.2 %EDTA 
added. Fifty microliter of 0.4 % Trypan Blue (MediaTech) 
added to clean eppendorf tube. The trypsinized cells were 
added to this same eppendorf tube. After 5 min, 10 μl of 
the suspended cells were added to a Bright-Line Hemacy-
tomer (Hausser Scientific). Only live cells were counted. 
The relative cell survival was calculated and defined as a 
percentage of the control cell number.
Statistical analysis
Student’s t test was used in statistical analysis of experi-
mental data. The p value less than 0.05 is considered as 
statistical significance.
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